Expression of Chimeric Polypeptide with Variable Lymphocyte Receptors on Immune Cells and Uses for Treating Cancer
US-2017008947-A1 · Jan 12, 2017 · US
Polypeptide capable of binding to vascular endothelial growth factor, and use thereof
US10508138B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10508138-B2 |
| Application number | US-201515737937-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 16, 2015 |
| Priority date | Jun 19, 2015 |
| Publication date | Dec 17, 2019 |
| Grant date | Dec 17, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to a novel polypeptide capable of binding specifically to vascular endothelial growth factor, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a recombinant microorganism including the expression vector, a method of producing the polypeptide using the recombinant microorganism, a composition for treating or preventing age-related macular degeneration or cancer, which comprises the polypeptide, and a method for preventing or treating age-related macular degeneration or cancer, which comprises administering the composition for treating or preventing age-related macular degeneration or cancer, which comprises the polypeptide. The disclosed polypeptide is capable of binding to vascular endothelial growth factor to inhibit the activity thereof, and thus can be widely used as an agent for treating and preventing various diseases associated with vascular endothelial growth factor (VEGF).
First claim
Opening claim text (preview).
The invention claimed is: 1. A polypeptide capable of binding to vascular endothelial growth factor (VEGF) comprising the amino acid sequence of any one of SEQ ID NOs: 3 to 8. 2. The polypeptide of claim 1 , wherein the polypeptide inhibits the activity of VEGF upon binding thereof. 3. A composition for treating age-related macular degeneration, comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
from bacteria · CPC title
Cytokines; Lymphokines; Interferons · CPC title
Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes} · CPC title
Fusion polypeptide · CPC title
Ophthalmic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10508138B2 cover?
- The present disclosure relates to a novel polypeptide capable of binding specifically to vascular endothelial growth factor, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a recombinant microorganism including the expression vector, a method of producing the polypeptide using the recombinant microorganism, a composition for treating or preventing age-related …
- Who is the assignee on this patent?
- Korea Advanced Inst Sci & Tech
- What technology area does this patent fall under?
- Primary CPC classification C07K14/461. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).